Abbott BD, Buckalew AR, DeVito MJ, EGF and TGF-alpha expression influence the developmental toxicity of TCDD: dose response and AhR phenotype in EGF, TGF-alpha, and EGF+TGF-alpha knockout mice

Abbott BD, Buckalew AR, DeVito MJ, EGF and TGF-alpha expression influence the developmental toxicity of TCDD: dose response and AhR phenotype in EGF, TGF-alpha, and EGF+TGF-alpha knockout mice. useful for? The high efficacy of acid suppressants and eradication regimens probably limit the value of such approaches for oesophagitis and peptic ulceration, except in the most intractable of cases. There are however a number of serious gastrointestinal pathologies where novel therapies might show useful, including their use for multiorgan failure,4 necrotising enterocolitis,5 and liver protection and regeneration.6 Three conditions worthy of particular focus are short bowel syndrome, chemotherapy induced mucositis, and inflammatory bowel disease. These are discussed further below. 2002;161:373C9. [PMC free article] [PubMed] [Google Scholar] 5. Sullivan PB, Brueton MJ, Tabara Z, Epidermal growth factor in necrotizing enterocolitis. Lancet 1991;338:53C4. [PubMed] [Google Scholar] 6. Caballero ME, Berlanga J, Ramirez D, Epidermal growth factor reduces multiorgan failure induced by thioacetamide. Gut 2001;48:34C40. [PMC free article] [PubMed] [Google Scholar] 7. Playford RJ, Boulton R, Ghatei MA, Comparison of the effects of TGF and EGF on gastrointestinal proliferation and hormone release. Digestion 1996;57:362C7. [PubMed] [Google Scholar] 8. OLoughlin W , Winter M, Shun A, Structural and functional adaptation following jejunal resection in rabbits: effect of epidermal growth factor. Gastroenterology 1994;107:87C93. [PubMed] [Google Scholar] 9. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002;122:531C44. [PubMed] [Google Scholar] 10. Jeppesen PB, Hartman B, Thulesen J, Elevated plasma glucagons-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2002;47:370C6. [PMC free article] [PubMed] [Google Scholar] 11. Hirano M , Mirin Iweakiri R, Fujimoto K, Epidermal growth factor enhances repair of rat intestinal mucosa damaged after oral administration of Mirin methotrexate. J Gastroenterol 1995;30:169C76. [PubMed] [Google Scholar] 12. Sonis ST, Lindquist L, Van Vugt A, Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3. Cancer Res 1994;54:1135C8. [PubMed] [Google Scholar] 13. Howarth GS, Francis GL, Cool JC, Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 1996;126:2519C30. [PubMed] [Google Scholar] 14. Gordler NM, McGurk M, Aqual S, The effect of EGF mouthwash on cytotoxic-induced oral ulceration. Am J Clin Oncol 1995;18:403C6. [PubMed] [Google Scholar] 15. Procaccino F , Reinshagen M, Hoffman P, Protective effect of epidermal growth factor in an experimental model of colitis. Gastroenterology 1994;107:12C17. [PubMed] [Google Scholar] 16. Sinha A , Nightingale JM, West KP, Epidermal growth factor (EGF) enemas treat ulcerative colitis. New Engl J Med 2003;349:350C7. [PubMed] [Google Scholar] 17. Khan Z , Macdonald C, Wicks AC, Use of the nutriceutical, bovine colostrum, for the treatment of distal colitis. Aliment Pharmacol Ther 2002;16:1917C22. [PubMed] [Google Scholar] 18. Sandborn WJ, Sands BE, Wolf DC, Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 2003;17:1355C64. [PubMed] [Google Scholar] 19. Verschraegen CF, Westphalen S, Hu Mirin W, Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Mirin Oncol 2003;90:552C9. [PubMed] [Google Scholar] 20. Emons G , Grundker C, Gunthert AR, GnRH antagonists in the treatment of gynaecological and breast cancers. Endocr Relat Cancer 2003;10:291C9. [PubMed] [Google Scholar] 21. Salomon DS, Brandt R, Ciardiello F, Epidermal-growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol/Haematol 1995;19:183C232. [PubMed] [Google Scholar] 22. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241C50. [PubMed] [Google Scholar] 23. Ciardiello F , Caputo R, Bianco R, Antitumour effect and potentiation of cytotoxic drugs activity in human malignancy cells by ZD1839 (Iressa) an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053C63. Mirin [PubMed] [Google Scholar] 24. Saltz LB, Meropol NJ, Loehrer PJ, Phase II trial of Cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1177C9. [PubMed] [Google Scholar] 25. Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003;30:39C50. [PubMed] [Google Scholar] 26. Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer brokers. Drugs 2000;59:753C67. [PubMed] [Google Scholar] 27. Jenkins PJ, Fairclough PD, Richards T, Acromegaly, colonic polyps JWS and carcinoma. Clin Endocrinol (Oxf) 1997;47:17C22. [PubMed] [Google Scholar] 28. Thulsen J , Hartmann B, Hare KJ, Glucagon-like peptide 2 (GLP-2) accelerates the.